Xcout IntelNervGen Pharma Corp. competitors & alternatives
The 12 closest competitors and alternatives to NervGen Pharma Corp. among biotech companies — ranked by similarity to what NervGen Pharma Corp. actually does, not by market-cap band.
Subscribe to see NervGen Pharma Corp.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About NervGen Pharma Corp.
NervGen Pharma Corp. is a biotechnology enterprise currently in its clinical development phase, focused on devising therapeutic solutions for nerve injuries and progressive neurodegenerative diseases. Their innovative approach centers on deactivating the natural biological mechanisms that typically impede the nervous system's ability to repair itself.
NervGen Pharma Corp. at a glance
NervGen Pharma Corp. is a biotech company headquartered in West Vancouver, Canada. It is publicly listed (NGEN) with a market capitalisation of $134M. Xcout tracks 11 named people at NervGen Pharma Corp., including Adam H. Rogers (President, CEO & Chairman).
NervGen Pharma Corp. leadership
- Adam H. RogersPresident, CEO & Chairman
- Keith A. VendolaChief Financial Officer
- Randall E. KayeChief Medical Advisor & Director
- Shamim RuffChief Regulatory Affairs Officer
- Harold Martin PunnettCo-Founder & Independent Director
- Charles V OlsonSenior Vice President of Technical Operations
5 more named people on record for NervGen Pharma Corp., with roles, board committees and tenure — see the full roster →
Top 12 NervGen Pharma Corp. competitors
Ranked by semantic similarity — how close each company is to NervGen Pharma Corp. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
FIVE DISCOVERY Corp is a biotechnology company that develops non-hallucinogenic neuroplastogen therapeutics designed to repair and stabilize dysfunctional neural circuits. The company serves patients suffering from neurodegenerative conditions and brain injuries, including Alzheimer's disease, Parkinson's disease, and traumatic brain injury.
Biotechnology
Neurasic Therapeutics is a biotechnology company headquartered in Montreal, Canada, created to advance groundbreaking research into novel therapeutics.
Biotechnology
NovaGo Therapeutics is a clinical-stage Swiss biotech company located in Schlieren that develops human antibody therapeutics focused on nerve growth and regeneration.
Similar biotech company
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
Similar biotech company
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Biotechnology
Asceneuron is a biotechnology research company founded in 2012 and headquartered in Eysins, Switzerland, focusing on the discovery and development of therapeutics for neurodegenerative disorders.
Biotechnology
Vigil Neuroscience is a biotechnology company headquartered in Massachusetts that harnesses the power of microglia for the treatment of neurodegenerative diseases.
Biotechnology
Recognify Life Sciences is a clinical-stage biotechnology company located in California, focusing on developing treatments for cognitive impairment associated with central nervous system disorders.
Biotechnology
Regenacy Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts. The company focuses on developing breakthrough treatments for diabetic neuropathies and other debilitating conditions.
Biotechnology
ProJenX, Inc. is a clinical-stage biotechnology company founded in 2021 and headquartered in New York City. The firm focuses on neuroscience, developing novel, brain-penetrant therapies targeting biologically defined motor neuron diseases such as ALS. It advances research programs aimed at addressing severe neurodegenerative conditions.
Biotechnology
Myrobalan Therapeutics is a pre-clinical biotechnology company headquartered in Medford, Massachusetts, focused on developing oral small molecule therapies for central nervous system and neurodegenerative diseases. The company targets novel mechanisms to create neurorestorative treatments for CNS disorders.
Biotechnology
Axonis Therapeutics, Inc. is a biotechnology company headquartered in Boston, Massachusetts, focused on discovering and developing novel treatments for neurological conditions and spinal cord injuries. Founded in 2019, the company advances therapeutic candidates through its proprietary research platform.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of NervGen Pharma Corp. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for NervGen Pharma Corp.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →